Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore

Govt. launches Mobile Health Service 'Kilkari' and Mobile Academy in Maharashtra and Gujarat

Kilkari programme aims to offer weekly services, timely accessible, accurate and pertinent 72 audio messages through IVRS about reproductive maternal, neonatal and child health care

American Cancer Society and Pfizer announce a US $15 million initiative to bridge the gap in cancer care disparities

The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM

Unichem Laboratories posts Q3 FY24 consolidated PAT at Rs. 83.99 Cr

Unichem Laboratories has reported total income of Rs. 445.65 crores during the period ended December 31, 2023

Aurobindo Pharma’s Eugia US Manufacturing to sell business assets to Empower Clinic Services for US$ 52 million

Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr

Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours

Submission to be reviewed under FDA real-time oncology review and Project Orbis

Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40